Drugs / Coprelotamab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04175171 | Nov 2011 → Jan 2012 | breast cancer | Genor Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coprelotamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04175171 ↗ |
| Route | Intravenous | “The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.” NCT04175171 ↗ |